And The Ride Hasn't Got Any Smoother In Recent Times Over The Last Year, With The Price 25% Lower In That Time . Furthermore, It's Down 11% in About a Quarter. That's Not Much Fun For Holders . ...
SIGUIENTE ... : " IDEAYA BIOSCIENCES HA INICIADO UNA COLABORACIÓN CLÍNICA Con ASTRAZENECA " Para Probar el Conjugado Anticuerpo-Fármaco en Fase de Investigación IDE849 , Dirigido Contra la Proteína DLL3 TOP1 , Junto Con el Inhibidor de PD-L1 DURVALUMAB ( IMFINZI de ASTRAZENECA ) , en PACIENTES con SMALL CELL LUNG CANCER EXTENSIVE-STAGE .... ¿ PORQUE NO ELIGIERON AL ATEZOLIZUMAB ... ?
And The Ride Hasn't Got Any Smoother In Recent Times Over The Last Year, With The Price 25% Lower In That Time . Furthermore, It's Down 11% in About a Quarter. That's Not Much Fun For Holders . ...